Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Expenses: 2021-2024

Historic Operating Expenses for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $402.1 million.

  • Amylyx Pharmaceuticals' Operating Expenses fell 52.64% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.7 million, marking a year-over-year decrease of 66.57%. This contributed to the annual value of $402.1 million for FY2024, which is 17.58% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Operating Expenses stood at $402.1 million for FY2024, which was up 17.58% from $342.0 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Operating Expenses' 5-year high stood at $402.1 million during FY2024, with a 5-year trough of $83.0 million in FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Operating Expenses value was $342.0 million (recorded in 2023), while the average stood at $322.6 million.
  • Data for Amylyx Pharmaceuticals' Operating Expenses shows a peak YoY soared of 169.45% (in 2022) over the last 5 years.
  • Over the past 4 years, Amylyx Pharmaceuticals' Operating Expenses (Yearly) stood at $83.0 million in 2021, then skyrocketed by 169.45% to $223.6 million in 2022, then spiked by 52.96% to $342.0 million in 2023, then climbed by 17.58% to $402.1 million in 2024.